Genzyme To Cough Up $64M To Settle Suit

Law360, New York (August 10, 2007, 12:00 AM EDT) -- Biotechnology company Genzyme Corp. will pay $64 million to settle a four-year-long squabble with shareholders over changes to the company's stock structure.

The settlement, which has yet to be filed in the U.S. District Court for the Southern District of New York, still needs court approval.

The company announced the deal in the class action on Thursday, saying that settling was in the best interests of all the parties.

Genzyme said, though, it still believes that its contested consolidation of the company's tracking stock structure “was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.